Inmed pharmaceuticals submits clinical trial applications to evaluate inm-755 (cannabinol) cream in a phase 2 trial for epidermolysis bullosa

Vancouver, british columbia, april 28, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm; tsx:in), a world leader in the clinical development of cannabinol (“cbn”), today announced that it has filed clinical trial applications (“ctas”) in austria, israel and serbia as part of a phase 2 clinical trial of inm-755 (cannabinol) cream in epidermolysis bullosa (“eb”). additional ctas for 755-201-eb (the ‘201 study) will be submitted to national competent authorities (“ncas”) and ethics committees (“ecs”) in france, germany, greece, and italy in the coming weeks.
INM Ratings Summary
INM Quant Ranking